ABSTRACT

Coronavirus disease 2019 (COVID-19), caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is currently responsible for a global pandemic. To date, only remdesivir and dexamethasone have demonstrated a positive response in a prospective, randomized trial for the treatment of patients with COVID-19. Hydroxychloroquine (HCQ) is an agent available in an oral formulation with in vitro activity against SARS-CoV-2 that has been suggested as a potential agent. Unfortunately, results of randomized trials evaluating HCQ as treatment against a control group are lacking, and little is known about its pharmacokinetic/pharmacodynamic (PK/PD) profile against SARS-CoV-2. The objective of this review was to describe the current understanding of the PK/PD and dose selection of HCQ against SARS-CoV-2, discuss knowledge gaps, and identify future studies that are needed to
optimize the efficacy and safety of treatments against COVID-19.

**Keywords:** COVID-19; Hydroxychloroquine; Pharmacodynamics; Pharmacokinetics

| Key Summary Points |
|--------------------|
| Information regarding pharmacokinetic/pharmacodynamic (PK/PD) properties of hydroxychloroquine (HCQ) against SARS-CoV-2 are lacking. |
| This review describes the current understanding of PK/PD properties and dose selection of HCQ against SARS-CoV-2. |
| This review also discusses knowledge gaps that are needed to optimize efficacy/safety of treatments against COVID-19. |

**INTRODUCTION**

The 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for coronavirus disease 2019 (COVID-19), was first identified in a group of patients that had contracted pneumonia-like illness of unknown etiology in Wuhan, China [1]. Despite variations in symptom severity, a subset of patients have been shown to progress to acute respiratory distress syndrome, often leading to mechanical ventilation and death [2]. Despite an impressive response by the medical community to identify therapies, the clinical efficacy of most potential antivirals remains uncertain [3]. To date, remdesivir has shown a moderate response effect (faster time to recovery) for patients with COVID-19 in a double-blind, randomized, placebo-controlled clinical trial (effect size greatest in those hospitalized patients requiring any supplemental oxygen); however, remdesivir is currently only available in limited rations and as an intravenous formulation, which may pose challenges [4]. Furthermore, dexamethasone (preliminary, unpublished data) has been shown to reduce 28-day mortality compared to usual care in hospitalized COVID-19 patients receiving oxygen or invasive mechanical ventilation. Theoretically, use of interleukin 6 (IL-6) inhibitors as immunomodulators and other immunomodulatory agents may be promising in severe cases, but supportive care currently remains one of the cornerstones of therapy for COVID-19 [5].

Hydroxychloroquine (HCQ) is an antimalarial agent with in vitro antiviral activity, anti-inflammatory effects, and immunomodulatory actions [6–8]. Given its wide availability and in vitro activity against SARS-CoV-2, HCQ became one of the earliest and most studied therapies for the treatment of and prophylaxis against COVID-19. Unfortunately, little is known about the appropriate dosage regimen(s) of HCQ to optimize efficacy and safety against COVID-19, as current knowledge is primarily derived from HCQ use in healthy volunteers and other non-COVID-19 disease states (e.g., malaria, rheumatoid arthritis, etc.) [9–13]. This is further highlighted by the fact that current enrolling clinical trials are utilizing different HCQ dosing regimens. Furthermore, there is considerable heterogeneity among studies regarding the pharmacokinetics (PK) sampling matrix (i.e., important because of varying concentrations depending on the matrix [blood versus plasma/serum]) and patient populations that have attempted to characterize HCQ’s PK/pharmacodynamic (PK/PD) properties against SARS-CoV-2.

Although studies completed thus far show variable results, Arshad and colleagues performed a large multicenter, retrospective, observational analysis that evaluated patients hospitalized because of a COVID-19-related admission receiving HCQ 400 mg twice daily on day 1, followed by HCQ 200 mg twice daily on days 2 to 5 [14–17]. When comparing HCQ monotherapy (n = 1202) versus no treatment (n = 409), in-hospital mortality was significantly lower in the HCQ monotherapy group (13.5% vs. 26.4%). Importantly, there was also significantly more steroid usage in the HCQ
monotherapy group compared to the no treatment group (78.9% vs. 35.7%), which may have contributed to this mortality difference [14]. Furthermore, the World Health Organization discontinued the HCQ arm in the Solidarity trial because it showed "little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care" (HCQ dosed 800 mg twice daily on day 1, followed by HCQ 400 mg twice daily for a total of 10 days), and the Food and Drug Administration revoked the emergency use authorization to utilize HCQ for the treatment of COVID-19 [16–18].

Given these critical gaps and inconsistencies in the literature, the objective of this review was to describe the current understanding of the PK/PD of HCQ for the treatment of COVID-19 as it relates to the efficacy and safety of dosage regimens. The focus of this review is on initial therapy of HCQ based on the most common treatment durations for COVID-19 (when available). Given the scarcity of literature on HCQ and similarities in mechanisms of action and chemical structure, data describing chloroquine in vitro activity will also be reviewed. We also discuss gaps in the literature and considerations going forward regarding in vitro and in vivo analyses of HCQ and other COVID-19 treatment options and identify future PK/PD studies that are needed to optimize the efficacy, if possible, and safety against COVID-19. It is important to note that the authors’ primary goal was to summarize and evaluate the PK/PD of HCQ to help clinicians in this challenging time. The summaries described are not meant to advocate for or endorse the widespread use of HCQ for the treatment of COVID-19. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

PHARMACOKINETIC PROPERTIES OF HYDROXYCHLOROQUINE

Absorption

Hydroxychloroquine is currently only available as an orally administered tablet, available in 200 mg as the sulfate salt form (equivalent to 155 mg base) [19]. There are numerous PK studies on the bioavailability of the oral tablet. However, most are in healthy volunteers or in patients with disease states other than COVID-19 [9–13]. Most studies have concluded that HCQ peak concentrations are estimated to be observed within 3–5 h [11,19,20]. In healthy males who received a single HCQ 200 mg oral dose, a mean peak blood HCQ concentration of 0.1296 mcg/ml was achieved in 3.26 h, while a peak plasma HCQ concentration of 0.0503 mcg/ml was achieved in 3.74 h. Tett and colleagues performed a randomized, crossover study in which the HCQ 155 mg oral tablet was compared to an intravenous infusion of racemic HCQ 155 mg to evaluate the absolute bioavailability of the commercially available HCQ tablet. These authors concluded that the mean (± SD) fraction of the oral dose absorbed (estimated from urine and blood) was 0.74 (± 0.13), while a wide range of absorption was calculated from plasma data [11,19].

Despite the lack of data and recommendations, current centers around the world have described crushing the HCQ tablets into suspensions and administering them via feeding tubes in patients otherwise unable to take oral medications, despite the Institute for Safe Medication Practices (ISMP) listing HCQ film-coated tablets on the “Do Not Crush” medication list [[21], direct communications]. Although this approach is commonplace in some inpatient centers among COVID-19 patients, there are no data on the impact of crushing HCQ tablets, administration via feeding tubes, and overall bioavailability or the timing of absorption. Given the uncertainty in PK with this approach, this further emphasizes the importance of understanding and optimizing PK and PD of HCQ against SARS-CoV-2.

Protein Binding

Most studies have shown that the binding of HCQ to protein is moderate (~ 40%) [9,22]. Albumin and alpha1-acid glycoprotein have been the two proteins associated with the majority of HCQ binding. HCQ exists as (R)-
and (S)-enantiomers, and stereoselective protein binding has been documented [22].

**Tissue Distribution**

It has been shown that HCQ exhibits linear PK [23]. Due to HCQ’s sequestration in deep tissues, the volume of distribution (Vd) that HCQ displays is extremely large. Tett and colleagues reported a blood and plasma Vd of 5522 l and 44,257 l, respectively, following intravenous HCQ infusion in healthy volunteers [23]. HCQ and chloroquine, which show similar patterns of tissue distribution, have been shown to concentrate quite highly in the lungs, kidney, liver, and spleen in animal models [24]. Maisonnasse and colleagues found that HCQ concentrations in the lung were higher than in plasma, with lung:plasma ratios ranging from 27 to 177 in macaques [25]. Notably, these data may very well be quite different in humans, and lung:plasma ratios could be lower because of differences in the metabolic composition and lower drug recovery rates.

**Metabolism and Transport Mechanisms**

CYP enzymes catalyze the dealkylation of HCQ to pharmacologically active metabolites, and HCQ/chloroquine has been documented to be metabolized through CYP 3A, 2D6, and 2C8 systems. The metabolism of HCQ leads to the three active metabolites, desethylhydroxycholoroquine, desethylchloroquine, and bisdesthelyhydroxychloroquine, although they have been shown to increase more significantly following chronic administration. It is anticipated that there are lower levels of these active metabolites present in the initial days of therapy for COVID-19 patients, and it is unclear how the various concentrations of active compounds translate to overall activity against SARS-CoV-2. Limited research has been conducted on investigating the association between genetic polymorphisms in CYP 3A, 2D6, and 2C8 and HCQ drug concentration levels [26–30].

Little is known about the role of membrane transporters on HCQ PK/PD. There is literature that suggests that HCQ inhibits uptake activity of human organic anion transporting polypeptide 1A2 [31]. Also, HCQ/chloroquine has been shown to be an inhibitor of p-glycoprotein [32].

**Excretion**

Reports have described a median of ~ 20% of HCQ being excreted renally as unchanged drug in humans [33,34]. Urinary elimination of HCQ as metabolites and unchanged drug has been reported to be between 6% and 60% [9,29,34]. Lim and colleagues reported HCQ clearance to be 15.5 l/h (two-compartment model best described these data). Most reports have described a terminal elimination half-life of 30–60 days (in contrast to a terminal blood half-life reported by Carmichael and colleagues of 43.3 h) [10,13]. Using plasma data following administration of the oral HCQ tablet, Tett and colleagues calculated a mean (± SD) terminal elimination half-life of 32 (± 9) days [11].

**Hydroxychloroquine/Chloroquine Mechanism, Concentration, and In Vitro Inhibitory Activity AGAINST SARS-CoV-2**

Although the mechanism of action of hydroxychloroquine and chloroquine against SARS-CoV-2 has not been fully elucidated, it is thought that these agents may prevent terminal glycosylation of its functional entry receptor (angiotensin-converting enzyme 2 receptor), thus inhibiting viral entry [6,7]. Furthermore, it has been shown that these agents can alkalinize intracellular compartments through incorporation of lysosomes and endosomes, leading to inhibition of viral replication and infection [8].

The majority of in vitro analyses of HCQ and chloroquine have utilized Vero cell lines (Table 1). Liu and colleagues evaluated the antiviral effects of HCQ against SARS-CoV-2 compared to chloroquine at four different multiplicities of infection (MOI) 48 h post-infection. At MOIs (0.01, 0.02, 0.2, and 0.8), the half maximal effective concentration (EC50) values for chloroquine (2.71, 3.81, 7.14, and 7.36 μM) and HCQ (4.51, 4.06, 17.31, and 12.96 μM), respectively, were determined.
Furthermore, the half cytotoxic concentration (CC$_{50}$) values were not found to be statistically significant from each other (chloroquine: 273.20 µM vs. HCQ: 249.50 µM) [35]. Wang and colleagues evaluated chloroquine against SARS-CoV-2 (nCOV-2019BetaCoV/Wuhan/WIV04/2019) and demonstrated potent in vitro activity in Vero E6 cells, which were infected at a MOI of 0.05. At 48 h, chloroquine was shown to potently inhibit SARS-CoV-2 with a EC$_{50}$ of 1.13 µM and CC$_{50}$ [100 µM]. This evaluation also showed that chloroquine worked at the "entry" and "post-entry" stages of SARS-CoV-2 infection [36].

Yao and colleagues performed an in vitro evaluation of HCQ and chloroquine against SARS-CoV-2-infected Vero cells at a MOI of 0.01 for 2 h, followed by treatment concentrations for 24 or 48 h. The authors concluded that HCQ was more potent than chloroquine, with EC$_{50}$ values of 6.14 µM and 23.90 µM, respectively, at 24 h and EC$_{50}$ values of 0.72 µM and 5.47 µM, respectively, at 48 h. Furthermore, HCQ was shown to exhibit a superior antiviral effect compared to chloroquine when cells were pretreated prior to viral challenge [37].

An evaluation from Maisonnasse and colleagues analyzed the in vitro activity of HCQ against SARS-CoV-2 in VeroE6 cells (MOI: 0.01) and a model of reconstituted human airway epithelium (MOI: 0.1). In VeroE6 cells at 48 and 72 h, the half maximal inhibitory concentration (IC$_{50}$) values were 2.19 µM and 4.39 µM, respectively. However, HCQ at 1 µM or 10 µM was not shown to significantly reduce viral titers in the reconstituted human airway epithelium at 48 h compared to untreated control [25].

Despite these in vitro evaluations, it is important to note that very little is known regarding the relevance of in vitro EC$_{50}$ values in optimizing the PK/PD of HCQ in humans. Furthermore, depending on testing conditions, the reported studies have reported a ~ 24-fold range in EC$_{50}$ values. Finally, it is currently unknown which cell line is optimal for showing activity, and the discordant results between different cell lines introduce additional uncertainty in the relevance of these values. These limitations further emphasize the need to define the “optimal target” and how to correlate this target to efficacious HCQ exposures.

**Table 1** Summary of in vitro EC$_{50}$ values reported for hydroxychloroquine/chloroquine from selected studies

| Author          | Medication     | Cell line | MOI | Time-point | EC$_{50}$ |
|-----------------|----------------|-----------|-----|------------|-----------|
| Liu et al. [35] | HCQ (chloroquine) | VeroE6    | 0.01 | 48 h       | 4.51 (2.71) |
|                 |                |           | 0.02 |            | 4.06 (3.81) |
|                 |                |           | 0.2  |            | 17.31 (7.14) |
|                 |                |           | 0.8  |            | 12.96 (7.36) |
| Wang et al. [36]| Chloroquine    | VeroE6    | 0.05 | 48 h       | 1.13      |
| Yao et al. [37] | HCQ (chloroquine) | Vero$^c$ | 0.01 | 24 h       | 6.14 (23.90) |
|                 |                |           |      | 48 h       | 0.72 (5.47) |
| Maisonnasse et al. [25] | HCQ | VeroE6    | 0.01 | 48 h       | 2.19$^d$ |
|                 |                |           |      | 72 h       | 4.39$^d$ |

$^a$ Post-infection  
$^b$ Expressed in µM  
$^c$ Not stated in article if VeroE6 was the lineage utilized  
$^d$ IC$_{50}$ (not EC$_{50}$)
PHARMACOKINETIC/PHARMACODYNAMIC ANIMAL STUDIES

Maisonnasse and colleagues evaluated the antiviral effect of HCQ both alone and in combination with azithromycin compared to placebo in SARS-CoV-2 infected macaques [10^6 PFU SARS-CoV-2 (BetaCoV/France/IDF/0372/2020) via combined intra-nasal and intra-tracheal routes]. The authors analyzed the PK of HCQ and stated that exposures in plasma were comparable to HCQ in humans at a dose of 200 mg three times daily at days 3 to 5. Neither the high- [90 mg/kg [human equivalent dose (HED) = 29.0 mg/kg] on day 1, followed by 45 mg/kg/day (HED = 14.5 mg/kg/day); n = 5] nor low-dose [30 mg/kg (HED = 9.7 mg/kg) on day 1, followed by 15 mg/kg/day (HED = 4.8 mg/kg/day); n = 4] regimens of HCQ accelerated the time to viral clearance compared to controls, despite showing that HCQ blood and lung concentrations of HCQ were higher than the EC50 values identified in VeroE6 cells. This lack of antiviral effect was further shown in the HCQ and azithromycin combination arm [25].

PHARMACOKINETIC/PHARMACODYNAMIC IN SILICO STUDIES FOR TREATMENT IN HUMANS

To date, limited PK/PD profiling studies have been performed to identify optimal dosage regimens against COVID-19 in humans, and the exposures targeted in these assessments are of questionable relevance. In a study conducted by Garcia-Cremades and colleagues, translational PK/PD modeling was used to propose optimized HCQ dosage regimens for initial treatment to ensure the highest likelihood of success (predict viral decline and risk of QTc prolongation). A published two-compartment population PK model for HCQ was used to predict plasma concentrations for different dosing regimens of HCQ (200 mg, 400 mg, 600 mg, and 800 mg twice daily for 5, 7, and 10 days, with and without various loading doses, and all simulations included 100 virtual patients that were simulated 1000 times). Evaluating the same EC50 range as previously published (0.72–17.31 μM), the authors of this study performed simulations by fixing one of the reported EC50 values, with each HCQ regimen simulated with each value 500 times, to determine HCQ’s effect on viral replication. The authors found that the extrapolated HCQ plasma concentration for the 50% viral inhibition value following simulations was 4.7 μM, and the authors’ targets were HCQ concentrations “close or above the clinical EC50 values and below 7.5 μM” for each simulation. Importantly, however, the authors do not provide sufficient support that these exposures would lead to the proposed results, and the data do not support > 7.5 μM as a toxic target. A mechanistic PK/virologic/QTc model for HCQ was developed, and a simulation study was performed to predict viral decline and QTc prolongation. The authors concluded that HCQ regimens > 400 mg twice daily for at least 5 days were predicted to rapidly decrease viral loads, while regimens > 600 mg twice daily were predicted to prolong QTc intervals (because of levels > 7.5 μM) [38].

Yao and colleagues used a physiologically based PK (PBPK) model for HCQ to simulate lung fluid HCQ concentrations under five HCQ dosing regimens to evaluate the most effective and safe regimen. Quantitative markers were ratios of estimated free lung tissue trough concentration to EC50 (RLTEC) based on human PK data and rat lung penetration data, which were compared to the “efficacious” chloroquine 500 mg twice daily that was reported to improve outcomes by Gao and colleagues [37,39]. Importantly, whether or not chloroquine 500 mg twice daily is an efficacious regimen is unclear as these data remain unpublished, and a recent report suggested high-dose chloroquine may be associated with increased toxicity and mortality [40]. The targeted HCQ RLTEC values were based on RLTEC values of 2.38, 5.92, and 18.9 on days 1, 3, and 5, respectively, simulated from the chloroquine 500 mg twice-daily regimen. All HCQ regimens produced RLTEC values higher than target RLTEC values for each day.
evaluated; however, the authors recommended HCQ 400 mg twice daily on day 1, followed by 200 mg twice daily for 4 days while “considering efficacy, safety, and patient compliance.” Furthermore, the R_LTEC values of HCQ were found to be higher than those of chloroquine on days 1, 3, 5, and 10. It is important to note that the HCQ EC_{50} values were \( \approx 7.6 \times \) less than those of chloroquine, which plays a role into HCQ’s higher R_LTEC values, and also that this enhanced potency is contrary to other in vitro analyses performed [37,41].

Perinel and colleagues performed a prospective analysis to characterize the PK of HCQ in patients admitted to the intensive care unit with laboratory-confirmed SARS-CoV-2 infection. Patients included in this analysis received initial HCQ regimens of 200 mg orally three times per day [42]. Based on previously published literature, HCQ trough values > 1 mg/ml and < 2 mg/ml were considered to “optimize efficacy and safety,” respectively [37,43]. It is important to note that there is no evidence in support of these values for optimal treatment against COVID-19. Thirteen patients were included in this analysis (12 of which were mechanically ventilated, 85% male), with a median age of 68 years (38–82 years), body weight of 82.7 kg (63.0–117.0 kg), and renal function of 79.6 ml/min (12.0–118.0 ml/min) as estimated via the CKD-EPI formula. Based on the HCQ initial regimen (200 mg orally three times/day), only 61% of patients achieved “therapeutic” levels (> 1 mg/ml) at a mean of 2.7 days (1.0–4.5 days), while 15% of patients achieved what the authors classified as “toxic” levels (> 2 mg/ml). To more clearly understand the variability of HCQ PK parameters and assess an optimal dosing regimen, a simulation study was performed across various dosing regimens. The authors proposed that a HCQ 800 mg loading dose on day 1 followed by 200 mg twice daily for 7 days provided “optimal” exposures (targeting levels > 1 mg/ml and < 2 mg/ml) compared to the other HCQ regimens simulated [42].

PHARMACOKINETIC/PHARMACODYNAMIC IN SILICO STUDIES FOR PROPHYLAXIS IN HUMANS

Al-Kofahi and colleagues performed simulations to model and identify possible pre- and post-exposure HCQ dosage regimens that would achieve target exposure over the SARS-CoV-2 EC_{50} and help guide clinicians in dose selection for COVID-19. Of note, the population PK parameters were derived from HCQ plasma concentrations from healthy volunteers and malaria patients, not patients with diagnosed COVID-19. The authors of this study chose to evaluate the percentage of patients with trough concentrations above the SARS-CoV-2 EC_{50} values of 0.72 \mu M and 1.44 \mu M (to account for plasma protein binding). These EC_{50} values were chosen as targets as lower EC_{50} values are typically associated with lower MOIs, and the authors presumed that post-exposure prophylaxis may be associated with lower viral loads compared to acute infection with SARS-CoV-2; however, there is no evidence to support this claim [44].

Regimens simulated included post-exposure prophylaxis one: no loading dose, followed by 400 mg daily for 5 days; post-exposure prophylaxis two: 800 mg loading dose, followed by 400 mg daily for 3 days; post-exposure prophylaxis three: no loading dose, followed by 200 mg three times daily for 6 days; post-exposure prophylaxis four: 800 mg loading dose, followed by 600 mg daily for 3 days; post-exposure prophylaxis five: 800 mg loading dose, followed by 600 mg daily for 5 days; and post-exposure prophylaxis six: 800 mg loading dose, followed by 600 mg daily for 7 days. With the exception of post-exposure prophylaxis regimen one, all other regimens had between 89 and 94% troughs above target on day 1, with a median time above target being 16–23 h. Post-exposure prophylaxis regimens three, five, and six maintained the optimal PD targets compared to the other regimens at day 14 [44]. Despite these results, it is currently unclear if the target chosen by the authors is, in fact, an appropriate target. Importantly, Boulware and colleagues...
conducted a randomized, double-blind, placebo-controlled trial assessing the effect of HCQ for post-exposure prophylaxis and found no significant difference in the incidence of new COVID-19 illness [45].

LIMITATIONS OF PHARMACOKINETIC/PHARMACODYNAMIC IN SILICO STUDIES FOR TREATMENT IN HUMANS

Overall, there are notable and important limitations across the highlighted studies. The primary limitation is that a proper exposure-response analysis was not performed in any of the human simulation studies. Targeted exposures were all related to published EC50 values to predict PD response, despite an absence of data to support this strategy. It is currently unknown if EC50 values are meaningful values and what exposures relative to these values would be associated with an antiviral effect. Furthermore, if EC50 values prove to be an effective target, it would be of importance to determine what conditions and cell line are associated with a reproducible and meaningful value. It warrants mention that the only true PD study currently available (Maisonnasse et al. [25] macaques study described above) failed to demonstrate an antiviral effect with HCQ despite having serum and lung concentrations above the EC50. Furthermore, if a target is identified, there is likely to be significant variation in PK in patients infected with COVID-19 that is not properly accounted for in the simulation studies published. When considering PK, it is also likely important to consider HCQ intracellular concentrations, as HCQ has been shown to accumulate in cells through “lysosomal trapping” [7]. Overall, there is a clear need for clinical data that links HCQ dose, PK, response, and safety in patients with COVID-19.

TOXICODYNAMICS

Although the most common adverse effects of HCQ are gastrointestinal in nature, ocular and cardiac toxicities are arguably the most concerning [46–49]. Ocular adverse effects associated with HCQ include retinopathy, corneal changes, and decreased visual acuity; however, these are most commonly associated with long-term use and would likely not be of principal concern with the short durations of HCQ utilized for COVID-19 [50]. Nevertheless, a recent report associated both maximum (p = 0.0340) and mean (p = 0.0124) HCQ levels to predict HCQ-induced retinopathy. In this report of 537 patients, the overall frequency of retinopathy was 4.3%. HCQ-induced retinopathy was found in 1.2%, 4.8%, and 6.7% of patients with a maximum HCQ blood concentrations of 0.0–1.2 mcg/ml, 1.2–1.8 mcg/ml, and 1.8–6.3 mcg/ml, respectively, and found in 1.2%, 3.7%, and 7.9% of patients with mean HCQ blood concentrations of 0.0–0.74 mcg/ml, 0.74–1.2 mcg/ml, and 1.2–3.5 mcg/ml, respectively. Notably, risk of retinopathy increased with HCQ duration, with only 1% of patients experiencing this adverse effect within the first 5 years of HCQ use [41].

The most immediate life-threatening adverse effect of HCQ is ventricular arrhythmias arising from QTc prolongation. Unfortunately, to our knowledge, there has been no evaluation linking HCQ exposure to cardiac toxicity. Evaluating a dose-response relationship with cardiac toxicities, including QTc prolongation, cardiomyopathy, torsades de pointes, and ventricular arrhythmia, is of utmost importance in future studies. It is also important to note that, although cardiac issues can arise with HCQ monotherapy, most cardiotoxicity is likely in combination with other drugs (e.g., azithromycin) or those with baseline pre-disposing conditions, such as baseline prolonged QTc and/or electrolyte abnormalities (although a dose-dependent effect with HCQ monotherapy is possible). In the evaluation conducted by Perinel and colleagues, QTc prolongation occurred in two patients receiving HCQ 200 mg orally three times/day, with QTc values elevating from 381 to 510 ms and 432 to 550 ms with HCQ levels of 0.03 mcg/ml and 1.74 mcg/ml, respectively. Given these large variations in HCQ levels, baseline comorbidities or concomitant QTc-prolonging medications could
have contributed to QTc prolongation; however, these potential confounding variables were not reported by the authors. A limitation of this study was that there were limited HCQ exposures that were correlated to toxicities. This evaluation utilized a “toxic” level of > 2 mcg/ml, which was derived as “…a number of arguments suggest that a concentration of 2 mcg/ml should not be exceeded to avoid ocular toxicity” [42]. Despite this basis, HCQ-induced ocular toxicity is most commonly associated with prolonged exposures and will likely be of less concern with the short durations utilized for COVID-19; cardiotoxicity is of much more concern during acute ingestion of HCQ [41,50]. Indeed, Mercuro and colleagues conducted a retrospective, observational study evaluating hospitalized COVID-19 patients and found that those receiving HCQ monotherapy had a median (IQR) change in QT interval of 5.5 [−15.5 to 34.3] ms [51]. Also important to note, given the large Vd and high tissue sequestration of HCQ, it is possible that patients may remain at risk for QTc prolongation after HCQ discontinuation. Baseline and periodic QTc monitoring should be used to help guide the safe use of HCQ in patients receiving this medication for COVID-19.

GAPS IN THE LITERATURE AND SUGGESTIONS FOR FUTURE STUDIES

Despite the work completed to date, many data need to be considered for the future testing of HCQ and other COVID-19 therapies to determine optimal dose(s) of these therapies. Antiviral “activity” in vitro and in vivo needs to be adequately defined (EC50, EC90, etc.) against SARS-CoV-2 in the most pertinent cell line. The previously cited in vitro studies display a broad range of EC50 values that were determined utilizing different MOIs and applying different time periods utilized for their samplings, despite the uncertainty of whether or not EC50 values are meaningful targets [35–37]. Further studies need to assess exposures in animal models in both blood and lung that are related to COVID-19 PD response (e.g., viral load reductions, resolution of symptoms, survival, etc.). Studies also need to further examine the penetration of HCQ into relevant tissues, taking into account intracellular concentrations (macrophages, neutrophils, etc.) due to “lysosomal trapping” associated with HCQ. When studying intracellular concentrations of HCQ, macrophage concentrations in humans need to be determined as concentrations will need to be corrected for if serum to macrophage concentrations differ between species. Following the optimal determination of the PD “target,” serum exposures in blood/plasma/serum should be correlated with lung concentrations throughout in vivo evaluations and then which dose(s) this translates to in humans needs to be determined. Following all of these considerations, these dosage regimens should be evaluated for efficacy and safety in well-designed, randomized clinical trials. Also, the current ongoing clinical trials will need to be evaluated for possible efficacy and safety signals associated with different dosage regimens.

Current dosing protocols and guidelines for HCQ are a result of extrapolating data and findings from other disease states and/or pharmacology simulation studies performed. Given the “cart before the horse” approach with HCQ in response to COVID-19, it will be important to examine the results of ongoing clinical trials to determine whether dose response(s) were observed (if any). It will be important to analyze possible differences in outcomes in those with mild versus moderate versus severe disease and whether combination therapy may be an effect modifier. COVID-19 is likely to be a clinical issue for the foreseeable future. If HCQ is shown to fail in clinical trials, this emphasizes the problem with relying on in vitro activity of antimicrobials to translate to improved patient outcomes. While the initial pandemic may not have afforded the opportunity for robust preclinical work to inform agent selection and dosing, this should not be the case moving forward. We have been able to work towards improving outcomes in patients with COVID-19 with non-pharmacologic approaches and (possibly) some potential treatment options in the interim; however, we as clinicians should learn from the mistakes made and attempt to
place the horse before the cart as we proceed with future therapies.

ACKNOWLEDGEMENTS

**Funding.** No funding or sponsorship was received for this study or publication of this article.

**Authorship.** All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. All authors have provided writing and editing assistance.

**Disclosures.** Taylor Morrisette, Thomas P. Lodise, Marc H. Scheetz, Srijib Goswami, and Jason M. Pogue have no relevant conflicts of interest to disclose. Michael J. Rybak is the Editor-in-Chief of this journal.

**Compliance with Ethics Guidelines.** This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/).

REFERENCES

1. World Health Organization (2020) WHO Timeline—COVID-19 [Internet]. https://www.who.int/news-room/detail/27-04-2020-who-timeline—covid-19

2. Guan WJ, Ni ZY, Liang WH, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2002032.

3. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JM. Pharmacologic treatments for coronavirus disease 2019 (COVID-19). JAMA. 2020. https://doi.org/10.1001/jama.2020.6019.

4. Beigel JH, Tomashek KM, Dodd LE, et al. (2020) Remdesivir for the treatment of COVID-19—preliminary report. N Engl J Med NEJMoa2007764

5. Zhang C, Wu Z, Li JW, Zhao H, Wang CG. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105954.

6. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Viro J. 2005;2:69.

7. Fantini J, Scala CD, Chahinian H, Yahu N. Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55:105960.

8. Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions, and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70:1608–21.

9. Tett SE, Day RO, Cutler DJ. Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis—a cross sectional study. J Rheumatol. 1993;20:1874–9.

10. Carmichael SJ, Charles B, Tett SE. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit. 2003;25:671–81.
11. Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27:771–9.

12. Fan HW, Ma ZX, Chen J, Yang XY, Cheng JL, Li YB. Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by LC-MS/MS. Rheumatol Ther. 2015;2:183–95.

13. Lim HS, Im JS, Cho JY, et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother. 2009;53:1468–75.

14. Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;S1201–9712(20):30534–8. https://doi.org/10.1016/j.ijid.2020.06.099.

15. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patient with COVID-19. N Engl J Med. 2020;382:2411–8.

16. World Health Organization (2020) “Solidarity” clinical trial for COVID-19 treatments [Internet]. World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments

17. Center for Drug Evaluation and Research (2020) FDA cautions use of hydroxychloroquine/chloroquine for COVID-19 [Internet]. U.S. Food and Drug Administration. FDA. https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or

18. ClinicalTrials.gov [Internet] (2020) Bethesda (MD): National Library of Medicine (US). 2000 Feb 29-. Identifier NCT04321616, The efficacy of different anti-viral drugs in COVID-19 infected patients; [about 6 screens]. https://clinicaltrials.gov/ct2/show/NCT04321616

19. Plaquenil [package insert] (2017) Concordia Pharmaceuticals Inc., St. Michael, Barbados

20. Tett SE, Cutler DJ, Day RO. Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. Pharm Sci. 1992;81:155–9.

21. Institute for Safe Medication Practices (ISMP) (2020) Oral dosage forms that should not be crushed. https://www.ismp.org/recommendations/do-not-crush. Accessed 20 Apr 2020

22. McLachlan AJ, Cutler DJ, Tett SE. Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites. Eur J Clin Pharmacol. 1993;44:481–4.

23. Tett SE, Cutler DJ, Day RO, Brown KF. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1988;26:303–13.

24. Popert AJ. Chorloquine: a review. Rheumatology. 1976;15:235–8.

25. Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non-human primates. 2020. https://doi.org/10.21203/rs.3.rs-27223/v1 (Pre-print).

26. Projean D, Baune B, Farinotti R, et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003;31:748–54.

27. Bauman JL, Tisdale JE. Chloroquine and hydroxychloroquine in the era of SARS-CoV2: caution on their cardiac toxicity. Pharmacother. 2020;40(5):387–8. https://doi.org/10.1002/phar.2387.

28. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther. 2007;20:160–74.

29. McChesney EW, Conway WD, Banks WF, et al. Studies of the metabolism of some compounds of the 4-amino-7-chloroquinoline series. J Pharmacol Exp Ther. 1966;151:482–93.

30. Lee JY, Vinayagamoorthy N, Han K, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2016;68:184–90.

31. Xu C, Zhu L, Chan T, et al. Chloroquine and hydroxychloroquine are novel inhibitors of human organic anion transporting polypeptide 1A2. J Pharm Sci. 2016;105:884–90.

32. Tiberghien F, Loor F. Ranking of p-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996;7:568–78.

33. Cutler DJ, MacIntyre AC, Tett SE. Pharmacokinetics and cellular uptake of 4-aminoquinoline anti-malarial. Agents Actions Suppl. 1988;24:142–57.

34. Browning D.J. Pharmacology of Chloroquine and Hydroxychloroquine. In: Hydroxychloroquine and Chloroquine Retinopathy. Springer, New York, NY.
2014. https://doi.org/10.1007/978-1-4939-0597-3_2.

35. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Dis. 2020;6:16.

36. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–71.

37. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa237.

38. Garcia-Cremades M, Solans BP, Hughes E, et al. Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug response. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1856.

39. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in the treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72–3.

40. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs. low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3:e208857.

41. Petri M, Elkahilfa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol. 2020;72:448–53.

42. Perinel S, Launay M, Botelho-Nevers E, et al. Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa394.

43. Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42:2092–7.

44. Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19: the desperate search for effectiveness. Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1874.

45. Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as post-exposure prophylaxis for COVID-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2016638.

46. Tetu P, Hamelin A, Lebrun-Vignes B, et al. Prevalence of hydroxychloroquine-induced side-effects in dermatology patients: a retrospective survey of 102 patients. Ann Dermatol Venereol. 2018;145:395–404.

47. Drent M, Proeisms VJJ, Elfferich MDP, et al. Ranking self-reported gastrointestinal side effects of pharmacotherapy in sarcoidosis. Lung. 2020;198:395–403.

48. Srinivasa A, Tosounidou S, Godon C. Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue? J Rheumatol. 2017;44:398.

49. O’Laughlin JP, Mehta PH, Wong BC. Life-threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Rep Cardiol. 2016;2016:4626279.

50. Jorge A, Ung C, Young LH, Melles RB, Choi HK. Hydroxychloroquine retinopathy-implications for research advances for rheumatology care. Nat Rev Rheumatol. 2018;14:993–703.

51. Mercuro NJ, Yen CF, Shim DJ. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020. https://doi.org/10.1001/jamacardio.2020.1834.

△ Adis